Alchemia loss grows on lower fondaparinux sales


By Dylan Bushell-Embling
Tuesday, 02 September, 2014


Alchemia loss grows on lower fondaparinux sales

Alchemia (ASX:ACL) has reported a wider net loss for the financial year ending in June, partly as a result of a declining share of profit from sales of anti-coagulant generic fondaparinux.

The company’s net loss increased to $6.9 million from $4.8 million. Its cash balance dipped 14.6% to a still solid $11.1 million.

Alchemia’s net profit share of fondaparinux sales by marketing partner Dr Reddy’s Laboratories fell to $8.1 million, from $9.6 million in FY13.

For the fourth quarter, profit share on fondaparinux sales was $1.62 million after accounting for the US$500,000 Alchemia will pay as part of its quarterly commitment towards reducing production costs.

Alchemia and Dr Reddy’s agreed in 2012 to invest $10 million between them to help maximise the profitability of fondaparinux sales. Alchemia’s equal share of this investment is being paid quarterly until the end of the calendar year.

Because the investment will be fully paid by next year, Alchemia said in an ASX announcement that it expects its profit share to improve in the future. Dr Reddy’s has also recently launched the product in Canada and will seek additional market approvals.

Towards the end the financial year, the company also commenced recruitment for a clinical trial of HA-Irinotecan in combination with cetuximub as a second-line therapy for metastatic colorectal cancer (mCRC).

Alchemia also expects to be ready to report top-line results from a major phase III trial, also in mCRC, by the end of the current quarter.

Alchemia (ASX:ACL) shares were trading 0.81% lower at $0.61 as of around 1.30 pm on Tuesday.

Related Articles

mRNA used to force HIV out of hiding

Using the same technology behind mRNA COVID-19 vaccines, researchers have discovered a way to...

Novel tool enables more precise gene therapy

A novel gene editor dubbed 'evoCAST' helps solve the problem of how to add long stretches...

Contact lens breakthrough lets humans see infrared light

Newly created contact lenses enable infrared vision in both humans and mice by converting...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd